Lilly Discontinues Phase III Rheumatoid Arthritis Program
Eli Lilly and Co. have discontinued its Phase III rheumatoid arthritis program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, because of lack of efficacy.
Drug Discovery Initiative Launched in Europe
An international consortium of pharmaceutical companies, academia, research organisations, and other related entities have launched a new platform to help enhance drug discovery in Europe.
GMP Compliance Becomes Prominent Enforcement Issue
Federal law enforcement officials and food and drug lawyers in the US anticipate a rise in legal actions involving lax adherence to cGMPs that result in adulterated products.
GSK Announces Fourth Quarter 2012 Results and 2013 Plans
GSK ended 2012 with Group sales down 1%, although sales were flat excluding prior-year comparisons related to over-the-counter product disposals.
Biogen Acquires Full Tysabri Rights from Elan
Biogen Idec has agreed to acquire full Tysabri rights from Elan, and will use its existing cash reserves to make a payment of $3.25 billion upon the closing of the transaction, as well as future contingent payments to Elan.
Lycera and MSD Collaborate on Autoimmune Therapies
The biopharmaceutical company Lycera has announced a collaboration agreement with Merck, Sharpe & Dohme (MSD) that will focus on developing and commercializing small-molecule therapies for treating a range of autoimmune diseases.
Pharma Companies Fight Healthcare Cost-Containment Policies in Europe
The ongoing economic crisis in Europe has accelerated healthcare cost-containment measures targeting the price of pharmaceuticals, but the pharma industry is not giving in without a fight.
A Call to Integrate Technology Innovation and Healthcare
In an article called “Beyond magic bullets: true innovation in health care,” scientists from Janssen encouraged the healthcare industry to think outside of the drug product-focused box and look at an integrated approach to care.
| 
